Corporate Communications
Week ending September 27, 2026
1. This week’s narrative in one paragraph
AI assistants are describing Ozempic in a cautious, label-oriented way, with most answers focused on safety, dosing, interactions, and who should not use it. The dominant public-facing message is that Ozempic is for adults with type 2 diabetes—not weight loss in people without diabetes—while weight-loss use is associated with the separate Wegovy brand. Answers repeatedly mention pancreatitis, low blood sugar, kidney injury linked to dehydration, pregnancy, and the thyroid C-cell tumor boxed warning. The tone is generally neutral and advisory rather than promotional; excerpts frequently direct people to a prescriber. The notable exception is competitive framing: Wegovy appeared in 11 answers, up from 9 last week, with limited new mentions of Trulicity, Mounjaro, and Zepbound.
2. Anything with public-story potential
-
Missed-dose guidance is visibly inconsistent. Answers split between taking a missed dose within 48 hours and taking it within five days. The public story would be: “AI assistants give people conflicting instructions about what to do after missing an Ozempic dose.” This is the clearest immediate communications risk because it is simple, actionable, and easy to screenshot.
-
AI answers vary in which safety information they include. For questions about interactions, kidney disease, pancreatitis, warnings, and dosing, some variants mention hypoglycemia, allergic reactions, kidney concerns, or contraindications while others omit them. The public story would be: “AI assistants cannot provide a consistent picture of Ozempic’s safety warnings.” The core thyroid-warning and pancreatitis narrative itself is broadly consistent, so this is a monitoring issue rather than an active crisis.
-
Ozempic/Wegovy brand distinction remains a recurring public-interest issue. Seven answers discuss off-label weight loss, and Wegovy is mentioned 11 times. The potential story would be: “People and AI continue to blur the line between Ozempic for diabetes and Wegovy for weight management.” This week does not show a rise in off-label discussion, but the topic remains highly visible.
3. Topics with a public-attention history
Safety concerns remain the most prominent recurring theme: pancreatitis (29 mentions), hypoglycemia (29), thyroid tumors (18), and pregnancy/lactation (14). Compounding is absent this week after appearing repeatedly through August and briefly in early September. Off-label discussion is down from 8 to 7, and no generic/biosimilar-substitution discussion is visible. Access, pricing, and supply framing do not appear in this dataset.
4. Trajectory
Overall inconsistency flags fell from 20 to 16, continuing the improvement from the August peak, while the safety-heavy narrative remains stable. Pancreatitis and hypoglycemia are slightly up week over week; contraindication, thyroid-tumor, boxed-warning, and off-label mentions are down. The missed-dose inconsistency appears newly salient in this week’s set, while broader safety variation is recurring.
5. Recommended actions
- Prepare a short holding statement/talking point on missed-dose guidance and verify the approved wording with Medical/Regulatory.
- Create a concise, source-based FAQ on Ozempic versus Wegovy, including approved-use framing; monitor for journalist or advocacy pickup.
- Brief PV and Medical Affairs on the recurring variation in AI safety answers, while keeping the Comms focus on potential public confusion.
- Monitor only for compounding, substitution, access, and pricing narratives; no proactive response is indicated this week.